Bacillus subtilis inhibits intestinal inflammation and oxidative stress by regulating gut flora and related metabolites in laying hens

Zou, X.Y.; Zhang, M.; Tu, Wen‐Jun; Zhang, Q.; Jin, Minghua; Fang, Rendong; Jiang, Sha

doi:10.1016/j.animal.2022.100474

Cited by 33 publications

(24 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found highly potentially associated with diet-induced obesity and nonalcoholic fatty liver disease-related parameters in serum and liver in previous studies ( Li et al, 2020 ; Duan et al, 2022 ). In addition, several beneficial microbes, such as Candidatus_Soleaferrea , were increased in pioglitazone monotherapy group ( Zou et al, 2022 ). Briefly, both metformin and pioglitazone monotherapy revealed significant effects on gut microbiota modification in our HFD-fed mice.…”

Section: Discussionmentioning

confidence: 99%

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

et al. 2022

View full text Add to dashboard Cite

Metformin and pioglitazone monotherapy have been proven to alter gut microbiota in diabetes and obesity. The present study aimed to investigated whether the combined administration of pioglitazone and metformin achieved superior protective effects on high-fat diet (HFD)-fed obese mice and elucidated its molecular mechanism via the gut microbiota and its metabolites. C57BL/6 males were randomly divided into five groups: the control group, fed a normal control diet; the HFD group, fed an HFD; the metformin monotherapy group, fed an HFD and treated with metformin; the pioglitazone monotherapy group, fed an HFD and treated with pioglitazone; and the combination therapy group, fed an HFD and treated with metformin and pioglitazone combination therapy. The cecal contents were collected for 16S rDNA amplicon sequencing and untargeted metabolomics analysis. The results showed that the combination therapy of metformin and pioglitazone significantly improved insulin sensitivity and glucolipid metabolism in HFD-fed mice. Combination therapy markedly altered gut microbiota by increasing beneficial bacteria, such as Bifidobacterium, Christensenellaceae_R-7_group, Faecalibacterium and Roseburia, and decreasing harmful bacteria, such as Oscillibacter and Eubacterium_xylanophilum_group. Fecal metabolites were significantly changed in the combination therapy group, including a reduction in amino acid metabolism and augmentation of lipid metabolism, such as citrulline, sarcosine, D-glutamine, lipoxin A4, prostaglandin E2, stearidonic acid and lucidenic acid A. These results revealed that combined metformin and pioglitazone therapy had synergistic effects or at least have an additive effect on modifying gut microbiota and metabolites, closely associated with improved glucolipid metabolic parameters in HFD-fed mice, which provides novel evidence and promising targets for metformin and pioglitazone combination therapy in type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Bacillus subtilis is a probiotic with the advantages of modulating the immune response, remodelling gut microbiota, short fermentation cycle and economic benefits (Zou et al, 2022). Preliminary studies have shown that a novel cyclic lipopeptide from Bacillus subtilis CAU21 (Liu et al, 2017), as well as bacteriocin (BAC‐IB17) produced by Bacillus subtilis KIB17 (Ansari et al, 2018), has good anti‐infection effects.…”

Section: Introductionmentioning

confidence: 99%

Bacillus subtilis WB800N alleviates diabetic wounds in mice by regulating gut microbiota homeostasis and TLR2

Xie

Zeng

et al. 2022

Journal of Applied Microbiology

View full text Add to dashboard Cite

Objective: This study aims to investigate the effect of Bacillus subtilis WB800N on diabetic wounds. Methods: Haematoxylin & eosin (H&E) staining was used to observe the healing of skin wounds. Collagen deposition was assessed by Masson staining. Western blotting and qRT-PCR were used to detect vascular endothelial-related factors (VWF), CD31, TLR2, NLRP3, ASC and Caspase-1 expression. 16S rDNA sequencing detected microbiota distribution. The concentrations of IL-1β and IL-37 were measured by ELISA. Apoptosis was measured by the TUNEL assay. Results: Compared with the control group, wound healing was delayed in diabetic mice. The wound area in the Bacillus subtilis group decreased more significantly than the diabetic wound group. H&E staining showed that Bacillus subtilis WB800N promoted wound healing and increased re-epithelialization. Masson staining showed that Bacillus subtilis WB800N increased collagen deposition in mice with diabetic wounds. Bacillus subtilis WB800N upregulated VWF and CD31 protein expression in diabetic wounds mice. The 16S rDNA results showed that Bacillus subtilis WB800N reduced the diversity of the gut microbiota of diabetic wounds mice and regulated the microbial composition. At the genus level, Bacillus subtilis WB800N reduced the relative abundance of Muribaculaceae and CG − 005 in diabetic wounds mice, whilst increasing the relative abundance of Lactobacillus. Bacillus subtilis WB800N increased the expression of TLR2, NLRP3, ASC and Caspase-1. Bacillus subtilis WB800N increased the concentrations of IL-1β and IL-37 in serum. Bacillus subtilis WB800N upregulated cell apoptosis. The TLR2 antagonist Sparstolonin B (SsnB) reduced the expression of TLR2, NLRP3, ASC, Caspase-1, IL-1β and IL-37 and the apoptosis in diabetic wounds mice, whilst the combined intervention of Bacillus subtilis and SsnB reversed the effect of SsnB treatment alone.

show abstract

“…Of the differentially abundant microbes, Candidatus Soleaferrea stands out for being absent in fCD infants but present in approximately 20% of the control cohorts. There is evidence that Candidatus Soleaferrea , which was absent in fCD infants, has anti-inflammatory properties, but this genus has also been correlated with several autoimmune diseases including CD ( Cai et al., 2020 ; Cao et al., 2021 ; Zou et al., 2022 ). Within each genus, species are diverse and have a range of metabolic features, which can have various consequences on host physiology.…”

Section: Discussionmentioning

confidence: 99%

Gut microbiome markers in subgroups of HLA class II genotyped infants signal future celiac disease in the general population: ABIS study

Milletich

Ahrens²,

Russell³

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Although gut microbiome dysbiosis has been illustrated in celiac disease (CD), there are disagreements about what constitutes these microbial signatures and the timeline by which they precede diagnosis is largely unknown. The study of high-genetic-risk patients or those already with CD limits our knowledge of dysbiosis that may occur early in life in a generalized population. To explore early gut microbial imbalances correlated with future celiac disease (fCD), we analyzed the stool of 1478 infants aged one year, 26 of whom later acquired CD, with a mean age of diagnosis of 10.96 ± 5.6 years. With a novel iterative control-matching algorithm using the prospective general population cohort, All Babies In Southeast Sweden, we found nine core microbes with prevalence differences and seven differentially abundant bacteria between fCD infants and controls. The differences were validated using 100 separate, iterative permutations of matched controls, which suggests the bacterial signatures are significant in fCD even when accounting for the inherent variability in a general population. This work is the first to our knowledge to demonstrate that gut microbial differences in prevalence and abundance exist in infants aged one year up to 19 years before a diagnosis of CD in a general population.

show abstract

Bacillus subtilis inhibits intestinal inflammation and oxidative stress by regulating gut flora and related metabolites in laying hens

Cited by 33 publications

References 66 publications

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

Bacillus subtilis WB800N alleviates diabetic wounds in mice by regulating gut microbiota homeostasis and TLR2

Gut microbiome markers in subgroups of HLA class II genotyped infants signal future celiac disease in the general population: ABIS study

Contact Info

Product

Resources

About